Skip to content
Pα+
  • My Pα+
  • Sign In
  • My Pα+
  • Sign In
Search
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
Search
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
Search
Join Pα+
  • My Pα+
  • Sign In
Menu
  • My Pα+
  • Sign In
Read more about the article DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

  • Post published:September 21, 2021
  • Post category:Press Release
Read more about the article DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

  • Post published:March 10, 2021
  • Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More